Navigation Links
Tolerx Presents Preclinical Data on Novel Cancer Immunotherapeutic, TRX518, a First-in-Class Anti-GITR Antibody

CAMBRIDGE, Mass., Feb. 9, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, presented results from preclinical studies with TRX518, a first-in-class immunomodulatory agent for the treatment of cancer. TRX518 is a monoclonal antibody reactive with the glucocorticoid-induced tumor necrosis factor receptor (GITR) and is designed to enhance the immune system's anti-tumor response by enabling T cells to more effectively attack cancer cells. The preclinical data were presented as a poster and invited talk at the Keystone Symposia "Antibodies as Drugs" meeting held in Keystone, Colorado. 

The presentation included a range of data from preclinical studies of TRX518 and details of the fully humanized TRX518 antibody. Results and data included:

  • A murine analog of TRX518 showed anti-tumor activity as a monotherapy and, when used as a combination therapy with standard chemotherapeutics, prevented the establishment of tumors, induced complete and partial remission of established tumors, and prolonged survival in animal models of human cancer.
  • The enhancement of the anti-tumor response afforded by anti-GITR combination therapy was shown to target specific immune responses, because these animal models were resistant to tumor re-challenge while other antigenically distinct tumors grew normally.
  • TRX518 blocked the interaction of GITR with its ligand, enhanced the cytotoxicity of natural human killer cells, downmodulated GITR on peripheral blood lymphocytes, did not induce appreciable cytokine release, and was well tolerated and safe at high doses in non-human primates.
  • Characterization of the TRX518 human clinical candidate, a fully humanized Fc-disabled anti-human GITR IgG1 mAb.  

Based on these data, a Phase 1, first-in-human, open label, dose escalation safety study in adults with Stage III/IV metastatic melanoma was initiated in December 2010 and is currently underway.

"We are very excited about the anti-GITR program, notably the unique and multifaceted mechanism of action and its promising safety profile," said Tony deFougerolles, Tolerx Chief Scientific Officer. "The preclinical data indicate that TRX518 has tremendous potential for enhancing anti-tumor responses, regardless of tumor type, and for also improving the effectiveness of other cancer therapies including chemotherapeutics and cancer vaccines."

About TRX518

TRX518 is an investigational immunotherapy designed to activate GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. GITR plays a role in directing the anti-tumor immune response via a multifaceted mechanism of action that includes activating tumor antigen-specific T effector cells, abrogating the suppression induced by T regulatory cells, and activating NK cells. In preclinical studies, TRX518 achieved its effect without compromising normal immune function, and preclinical models suggest TRX518 to have a favorable safety profile. A Phase 1 clinical study of TRX518, a first-in-class anti-GITR monoclonal antibody, has been initiated to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ascending single doses of TRX518 in patients with malignant melanoma. TRX518 is designed to have activating and sustaining effects on T cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including vaccines. 

About Tolerx

Tolerx, Inc., a world leader in immunology for novel drug development, has a portfolio of innovative, first-in-class drug candidates to treat autoimmune diseases, diabetes, and cancer by normalizing the immune system. The company's pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. Tolerx's product candidate, TRX518, is a targeted T cell immunotherapy in Phase 1 development for the treatment of cancer. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has two preclinical candidates, TRX585 and TRX385, which enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit

SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
2. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
3. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
4. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
5. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
6. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
7. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
8. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
9. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
10. Prime Therapeutics President and CEO Eric Elliott Presents Keynote Address at 2011 PCMA Managed Markets Educational Forum
11. Watson Presents Outlook for Continued Long Term Growth
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... for mental health and wellness consultation, has collaborated with Women’s Web – ... their reader’s queries on topics on mental and emotional well-being relationship, life ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... where preparing the perfect dish and pleasing the palates of attendees is of ... bringing a dish to a seasonal get-together, give these recipes a try this ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director ... about hair loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for ... and fuller hair, without the need for surgery, prescription pills, or topical foams. ...
(Date:11/25/2015)... ... November 25, 2015 , ... According to an article published November ... more widely heralded as a breakthrough for performing hernia repairs. The article explains that ... surgery is that it can greatly reduce the pain that a patient might otherwise ...
(Date:11/25/2015)... Raton, Florida (PRWEB) , ... November 25, 2015 ... ... diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under ...
Breaking Medicine News(10 mins):